Abstract: The invention relates to novel compounds denominated halocombstatins. The halocombstatins are derivatives of combretastatin A-3, and include compounds that exhibit cancer growth cell inhibition against a panel of human cancer cell lines and the murine P388 leukemia, as well as activity as inhibitors of tubulin polymerization and inhibitors of the binding of colchicine to tubulin.

Abstract: The invention relates to novel compounds denominated halocombstatins. The halocombstatins are derivatives of combretastatin A-3, and include compounds that exhibit cancer growth cell inhibition against a panel of human cancer cell lines and the murine P388 leukemia, as well as activity as inhibitors of tubulin polymerization and inhibitors of the binding of colchicine to tubulin.

Abstract: The Indo-Pacific marine sponge Ircinia ramosa has been found to contain two powerful (GI50 0.001 to <0.0001 ?g/ml) murine and human cancer cell growth inhibitors, denominated herein as irciniastatin A and irciniastatin B. Both were isolated (10-3 to 10-4% yields) by cancer cell line bioassay-guided techniques and named irciniastatins A (1) and B (2). Structural elucidation by a combination of spectral analyses, primarily high resolution mass and 2D-NMR (principally APT, HMQC, HMBC and ROESY) revealed unusual structures 1 and 2.

Abstract: Combretastatin A-4 has been previously selected for pre-clinical development as antineoplastic agent. However, it is essentially insoluble in water. New water soluble derivatives of combretastatin A-4 and its qualified analogs have been discovered and synthesized through a multistage process using other derivatives of combretastatin A-4 as intermediates. These water soluble derivatives are herein denominated as “Combretastatin A-4 Prodrugs”.

Abstract: A method for performing wavefront-guided laser surgery on a cornea includes the step of calculating a corneal flap configuration based upon collected anatomical information on an eye and wavefront data on a cornea of the eye. Such data may be collected by, for example, an aberrometer, although this is not intended as a limitation. The calculated configuration is transmitted to a processor in controlling relation to a corneal flap-cutting device. The flap-cutting device is used to create a corneal flap based upon the calculated configuration. A system for performing wavefront-guided laser surgery on a cornea includes a processor for receiving the anatomical information and wavefront data. A software package is adapted to calculate the corneal flap configuration and to control a corneal flap-cutting device to cut a corneal flap commensurate with the calculated corneal flap configuration.

Abstract: Cribrostatin 6, a dark blue cancer cell growth inhibiting constituent of the Republic of Maldives marine sponge Cribrochalina sp. has been isolated, and its structure (shown below) elucidated, based on a combination of RMS, high field (500 MHz, HMBC, and GOESY experiments) 15N, 1H- and 13C NMR, and X-ray crystal structure analyses. Cribrostatin 6 also was found to inhibit the growth of a number of pathogenic bacteria and fungi.

Abstract: The present invention provides prodrugs derived from the sparingly soluble anticancer isocarbostyril narciclasine, a component of various Narcissus species, said prodrugs having potential for use against animal and human cancers. Also disclosed is an efficient procedure for the synthetic conversion of narciclasine to several more soluble cyclic phosphate compounds, including “narcistatin”.

Abstract: Selective phosphorylation of phenpanstatin (3a) with tetrabutylammonium dihydrogen phosphate and dicyclohexyl-carbodiimide in pyridine followed by cation exchange chromatographic procedures was found to provide an efficient route to a new series (3b-3d) of promising 3,4-O-cyclic phosphate prodrugs designated phenpanstatin phosphates. Application of analogous reaction conditions to pancratistatin (1a) led to a mixture of monophosphate derivatives where sodium paancratistatin 4-O-phosphate (4a) was isolated and the structure confirmed by x-ray craxtallography. Modification of the reaction conditions allowed direct phosphorylation of pancratistatin followed by cation exchange chromatography to afford sodium pancratistatin 3,4-O-cyclic phosphate (5b) which was selected for preclinical development.

Abstract: Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.

Abstract: The present invention provides methods for treating inflammatory conditions, rheumatoid diseases, autoimmune conditions, and conditions associated with bone loss, comprising administering to a subject with an inflammatory condition an amount effective to treat the condition of a compound selected from the group consisting of narcistatin, pancratistatin, pancratastatin-7? phosphate and pancratastatin-3?,4? cyclic phosphate, or pharmaceutically acceptable salts thereof.

Abstract: Described herein are novel compounds having antineoplastic and antimicrobial activity, obtained via structural modifications of resveratrol and combretastatin A-4, methods for synthesis of these compounds, and their use in pharmaceutical composition and for use in the treatment of mammals having cancer. Examples of the novel compounds are: (Z)- and (E)-3,4?,5-trimethioxystilbene (4a, 4b); (Z)- and (E)-3,5-dimethoxy-4?-hydroxystilbene (14c, 14d); (Z)-and (E)-3-hydroxy-4?,5-dimethoxystilbene (14g, 14h);(Z)-and (E)-3,5-dihydroxy-4?-methoxy-stilbene (14k, 14l); sodium resverastatin dibenzyl phosphate ((Z)-3,5-dimethoxy-4-[O-bis(benzyl)phosphoryl]-stilbene) (14m); and sodium resverastatin phosphate (14n).

Abstract: Disclosed herein is the isolation and elucidation of the structure of isoaptamine (2), and its conversion to numerous novel related compounds, which appear to have antimicrobial and/or cancer fighting properties. Also disclosed is the conversion of isoaaptamine (2) to the phosphate prodrug hystatin 1 (11), as well as the conversion of aaptamine to numerous compounds, including but not limited to: 9-demethyloxyaaptamine (3); 4-methylaaptamine (4); 1,4-dimethylaaptamine iodide (5); 4-N-methyl-8,9-dihydroxy-4H benzo[de][1,6]naphthyridine (7); 4-N-methyl-8 methoxy-9 hydroxy-4H benzo[de][1,6]naphthyridine (8); 1-H-Benzo[de][1-6]naphthyridinium salts (9a-c); hystatin 2 (10a); and others.

Abstract: The invention relates to novel compounds denominated halocombstatins. The halocombstatins are derivatives of combretastatin A-3, and include compounds that exhibit cancer growth cell inhibition against a panel of human cancer cell lines and the murine P388 leukemia, as well as activity as inhibitors of tubulin polymerization and inhibitors of the binding of colchicine to tubulin.

Abstract: A system and method for tracking ocular changes during a surgical procedure include directing an eye-safe optical beam toward an undilated, unparalyzed eye. A reflected optical beam is detected, and measurements are performed based upon data contained in the reflected optical beam of at least one geometric parameter of the eye at a predetermined frequency, and from them is calculated a change in the at least one geometric parameter. The calculated change is used to dynamically adjust the directing of laser beam shots during the surgery.

Abstract: The original synthesis of combretastatin A-2 (1a) was modified to provide an efficient scale-up procedure for obtaining this antineoplastic stilbene. Subsequent conversion to a useful prodrug was accomplished by phosphorylation employing in situ formation of dibenzylchlorophosphite followed 30 by cleavage of the benzyl ester protective groups with bromotrimethylsilane to afford phosphoric acid intermediate 11. The latter was immediately treated with sodium methoxide to complete a practical route to the disodium phosphate prodrug (2a). The phosphoric acid precursor (11) of phosphate 2a was employed in a parallel series of reactions to produce a selection of metal and ammonium cation prodrug candidates. Each of the phosphate salts (2a-q) was evaluated with respect to relative solubility behavior, cancer cell growth inhibition, and antimicrobial activity.

Abstract: The antifungal and cancer cell growth inhibitory activities of 1-(3?,4?,5?-trimethoxyphenyl)-2-nitro-ethylene (TMPN) were examined. TMPN was fungicidal for the majority of 132 reference strains and clinical isolates tested, including those resistant to fluconazole, ketoconazole, amphotericin B or flucytosine. Minimum fungicidal concentration/minimum inhibitory concentration (MFC/MIC) ratios were ?2 for 96% of Cryptococcus neoformans clinical isolates and 71% of Candida albicans clinical isolates. TMPN was fungicidal for a variety of other basidiomycetes, endomycetes and hyphomycetes, and its activity was unaffected by alterations in media pH. TMPN was slightly cytotoxic for murine and human cancer cell lines (GI50=1-4 ?g/ml), and weakly inhibited mammalian tubulin polymerization (IC50=0.60 ?g/ml). TMPN may also be used as a biochemical probe for tubulin and fungal dimorphism studies.

Abstract: A method for optimizing a prescription for laser-ablation corneal treatment or ophthalmic implant includes the steps of receiving a measured correction prescription for a current patient having a classification element associated therewith, the prescription having been measured using wavefront determination. A database of treatment outcomes on a plurality of previously treated patients is accessed, each treated patient outcome having associated therewith at least one classification element and comprising a preoperative wavefront-determined correction prescription and a postoperative visual profile. From the treatment outcomes in the database is calculated an average difference between the preoperative prescription and the postoperative profile for at least some of the previously treated patients having a classification element in common with the current patient.

Abstract: An automated, objective method for determining the accommodative range and aberration profile of an eye using a wavefront sensor that iteratively determines the change in accommodation of the lens of an eye.

Abstract: A method for optimizing a prescription for laser-ablation corneal treatment or ophthalmic implant includes the steps of receiving a measured correction prescription for a current patient having a classification element associated therewith, the prescription having been measured using wavefront determination. A database of treatment outcomes on a plurality of previously treated patients is accessed, each treated patient outcome having associated therewith at least one classification element and comprising a preoperative wavefront-determined correction prescription and a postoperative visual profile. From the treatment outcomes in the database is calculated an average difference between the preoperative prescription and the postoperative profile for at least some of the previously treated patients having a classification element in common with the current patient.

Abstract: An automated, objective method for determining the accommodative range and aberration profile of an eye using a wavefront sensor that iteratively determines the change in accommodation of the lens of an eye.